Royalty Pharma sells 20% of its royalty interest in Ibrutinib

|By:, SA News Editor

Royalty Pharma says that pursuant to its collaboration with Aisling Capital and Clarus Ventures, it has sold the two companies around 20% of its royalty interest in Ibrutinib it recently acquired from Quest Diagnostics (DGX -0.2%).

In payment, its will receive a pro rata percentage of the $485M it paid to Quest for the royalty.

Pharmacyclics (PCYC +0.1%) and Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceuticals filed Ibrutinib with the FDA in July 2013 for the treatment of lymphoma and relapsed/refractory chronic lymphocytic leukemia, and currently has received three of the eight Breakthrough Therapy Designations granted by the FDA to date in oncology.